• Adaptimmune’s VP QA CMC Talks Quality Management
    Adaptimmune’s VP QA CMC Talks Quality Management

    One conversation with Michael Blackton, VP QA CMC at Adaptimmune, proves why he is known for being a passionate, results-oriented leader focused on QA, analytical development, and more. Validate for yourself as Blackton answers my questions about process development and quality management. And, he provides a fresh outlook on recruiting senior-level executives.  

  • Nontraditional Design Concepts To Accelerate CAR T Processing
    Nontraditional Design Concepts To Accelerate CAR T Processing

    Cell therapies, in particular, chimeric antigen receptor modified T cells (CAR-T), are showing enormous therapeutic promise, with cancer remission rates over 80 percent.1 This alone is forcing cell therapy manufacturing companies to develop strategies to build and scale up production at levels never contemplated before.

  • Cardiac Stem Cell Controversy — 3 Important Lessons Learned
    Cardiac Stem Cell Controversy — 3 Important Lessons Learned

    Heart problems have touched many of our lives, or the lives of those we care about. Heart attacks and heart failure are leading killers in the U.S.,1 with limited treatment options available today. Typically, a heart attack is followed by significant heart muscle cell death, leaving the organ in a weakened state and the patient at risk of cardiovascular dysfunction and eventual heart failure. This leads to many of the deaths attributed to cardiovascular disease.

Novartis Turns To Digital Technologies For Clinical Trials
Novartis Turns To Digital Technologies For Clinical Trials

Jake LaPorte, head of digital development for Novartis, talks about how AI, IoT, and machine learning are all being leveraged for better clinical trials.

  • Establishing A Critical Supply Chain For Autologous Cell And Gene Therapies
    Establishing A Critical Supply Chain For Autologous Cell And Gene Therapies

    With the recent breakthroughs in cell and gene therapy, there is increased emphasis on the design and implementation of different supply chain models to support the movement of materials and drug product across the chain of care. Unlike more traditional supply chains, many of these therapies have unpredictable sources and manufacturing and infusion locations. The most extreme example is loosely referred to as the “vein-to-vein” supply chain — particularly for autologous therapies.

  • A Patient’s Journey To Join A CAR-T Cell Therapy Trial
    A Patient’s Journey To Join A CAR-T Cell Therapy Trial

    Nicole Gularte is currently battling cancer for the 8th time. The last time she had to do so, it seemed a CAR-T cell therapy trial might be the solution. This article is about her long battle with cancer, the struggle to get into a CAR-T cell trial, and the ups and downs she has faced along the way. Her story is an inspiration to others.

  • Key Takeaways From FDA’s New Guidance On First-In-Human Multiple Expansion Cohort Trials
    Key Takeaways From FDA’s New Guidance On First-In-Human Multiple Expansion Cohort Trials

    The FDA published a new draft guidance on August 10, 2018 entitled, Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics. The comment period for the draft guidance closed on October 12, 2018 and approximately 20 comments were submitted to the docket. The guidance provides sponsors with recommendations for designing and conducting first-in-human (FIH) multiple expansion cohort trials within their oncology development programs.

  • 4 Emerging Commercialization Strategies For Gene And Cell Therapies
    4 Emerging Commercialization Strategies For Gene And Cell Therapies

    Progress in development of gene and cell therapies around the world has potential to transform standards of care for a range of diseases and address significant areas of unmet need in healthcare over the coming years. In the U.S. alone, almost 20 gene and cell therapy products have been approved thus far,1 with many other development programs reaching later clinical stages. The technology platforms of many of these drugs also offer the potential for curative efficacy and expansion for use in multiple indications.

  • ARM’s CEO Recaps 2018 Meeting On The Mesa
    ARM’s CEO Recaps 2018 Meeting On The Mesa

    Cell & Gene Meeting on the Mesa took place last month in La Jolla, CA, and it’s no surprise that ARM delivered meaningful data and addressed cutting-edge research to more than 1,200 attendees. I caught up with ARM’s CEO Janet Lambert after the Meeting to get her take on top highlights, the most informative panel discussions, as well as a look ahead to next year’s event. Here’s what she had to say.

  • Incorporating Patient-Centric Outcome Metrics In Rare Disease Trials
    Incorporating Patient-Centric Outcome Metrics In Rare Disease Trials

    Commercial viability of pharmaceuticals depends on getting medicines to patients, which requires developers to evaluate investigative therapies using outcomes that are quantifiable, easy to interpret, and clinically relevant. However, clinical relevance is often a matter of stakeholder perspective: what developers view as meaningful may not appear as such to patients and caregivers.

  • The Top 5 Trends To Watch In Bioprocessing
    The Top 5 Trends To Watch In Bioprocessing

    Biopharmaceutical processes — and the technologies that enable them — have experienced remarkable progress in the past 30 years, since the first biopharmaceuticals were approved for human use. This article will highlight some of today’s top trends in bioprocessing, as this exciting field continues to flourish.

  • Developing Control Strategies For Gene Therapy Products — What Role Should CMOs Play?
    Developing Control Strategies For Gene Therapy Products — What Role Should CMOs Play?

    CMOs are positioned to play a leading role in standardizing control strategies for gene therapy because so many gene therapy products are funneled through CMOs for commercial scale production.

  • Part 2: ISCT’s Miguel Forte On The Society’s Near-Term Goals
    Part 2: ISCT’s Miguel Forte On The Society’s Near-Term Goals

    In part two of my discussion with Miguel Forte, CEO at Zelluna Immunotherapy and ISCT’s Chief Commercialization Officer, he answers my questions about the Society’s near-term goals and objectives as well as his top areas of focus as CCO.

  • CMC For Cell & Gene Therapies: 4 Topics To Discuss During Pre-IND Meetings With FDA
    CMC For Cell & Gene Therapies: 4 Topics To Discuss During Pre-IND Meetings With FDA

    Seeking early guidance from regulators can be invaluable when navigating preliminary product development strategies. The need for feedback increases significantly when working with cell and gene therapy products. 

  • State Of The Cell And Gene Therapy Sector — Clinical, Financial, And Regulatory Perspectives
    State Of The Cell And Gene Therapy Sector — Clinical, Financial, And Regulatory Perspectives

    The regenerative medicine sector is at a remarkable moment. Transformative products are now on the market and accessible to greater numbers of patients every day. Dozens of additional therapies are in late stage studies. The regulatory and policy environment has evolved rapidly alongside the science, enabling a surge of incoming innovation.

  • Science Driving Gene Therapy Development At bluebird bio
    Science Driving Gene Therapy Development At bluebird bio

    For patients with sickle cell anemia, just getting through the day can be a struggle. Symptoms of the disease include vision problems, swelling of the hands and feet, and periodic episodes of pain that can last from a few hours to a few weeks. In this article Nick Leschly, CEO at bluebird bio, discusses the progress being made with its investigational gene therapy for sickle cell disease.

More From Cell & Gene

C&G EDITOR IN CHIEF, ERIN HARRIS

  • Adaptimmune’s VP QA CMC Talks Quality Management
    Adaptimmune’s VP QA CMC Talks Quality Management

    One conversation with Michael Blackton, VP QA CMC at Adaptimmune, proves why he is known for being a passionate, results-oriented leader focused on QA, analytical development, and more. Validate for yourself as Blackton answers my questions about process development and quality management. And, he provides a fresh outlook on recruiting senior-level executives.  

  • The Status of Regulatory Framework For Cell And Gene Therapies
    The Status of Regulatory Framework For Cell And Gene Therapies

    Jiwen Zhang, Executive Director, Regulatory Affairs at Tmunity Therapeutics Incorporated and Cell & Gene Editorial Advisory Board member explains the status of the cell and gene sector’s domestic and international regulatory framework. As President of the International Standards Coordinating Body (SCB), she also provides a synopsis of the most recent Stakeholder meeting.

  • ARM’s CEO Recaps 2018 Meeting On The Mesa
    ARM’s CEO Recaps 2018 Meeting On The Mesa

    Cell & Gene Meeting on the Mesa took place last month in La Jolla, CA, and it’s no surprise that ARM delivered meaningful data and addressed cutting-edge research to more than 1,200 attendees. I caught up with ARM’s CEO Janet Lambert after the Meeting to get her take on top highlights, the most informative panel discussions, as well as a look ahead to next year’s event. Here’s what she had to say.

  • Part 2: ISCT’s Miguel Forte On The Society’s Near-Term Goals
    Part 2: ISCT’s Miguel Forte On The Society’s Near-Term Goals

    In part two of my discussion with Miguel Forte, CEO at Zelluna Immunotherapy and ISCT’s Chief Commercialization Officer, he answers my questions about the Society’s near-term goals and objectives as well as his top areas of focus as CCO.

  • ISCT’s Miguel Forte On Academic-To-Industry Translation
    ISCT’s Miguel Forte On Academic-To-Industry Translation

    In part one of my discussion with Miguel Forte, CEO at Zelluna Immunotherapy and Chair of Commercialization Committee at ISCT, he answers my questions about academic-to-industry translation, the root cause of unproven therapies, how the industry is combatting them, and more.

  • CAR-T And The Voice Of The Patient
    CAR-T And The Voice Of The Patient

    Cell & Gene Editorial Advisory Board member answers questions about his message to pharma executives, researchers, scientists, and doctors, what the industry should consider when developing new payment structures, and more.

  • The FDA’s Dr. Peter Marks On The Current State Of Cell And Gene Therapies
    The FDA’s Dr. Peter Marks On The Current State Of Cell And Gene Therapies

    Peter Marks, MD, PhD, Director Center for Biologics Evaluation and Research at U.S. Food and Drug Administration answered some of my questions about the current state of the FDA’s regulations around cell and gene therapies, its stance on international harmonization required to make cell and gene therapies more streamlined, the reasons why it is critical for companies to begin working with the FDA early in the development process, and more. Read on for Dr. Marks' insightful responses.

  • A Sit Down With ARM’s CEO, Janet Lambert
    A Sit Down With ARM’s CEO, Janet Lambert

    Janet Lambert, joined the Alliance for Regenerative Medicine (ARM) as CEO just over a year ago. And what a year it’s been. Recently, I had the opportunity to talk to Lambert about her first year as CEO, what ARM is doing in cell and gene therapies from clinical and commercialization points of view, as well as its areas of short-term focus. Here’s what she had to say.

CELL AND GENE INDUSTRY EVENTS

Phacilitate Leaders World January 22 - 25, 2019
Miami, FL
Patients As Partners March 11 - 12, 2019
Philadelphia, PA
Car-T Congress USA March 20 - 22, 2019
Boston, MA
ARM Meeting on the Mediterranean April 23 - 24, 2019
Barcelona
American Society of Gene & Cell Therapy (AGCST) April 29, 2019 - May 2, 2019
Washington, DC
More Industry Events

INDUSTRY INSIGHTS

More Industry Insights